However, recent studies have revealed that YAP can function as a context-dependent tumor suppressor in several types of cancer including hematological cancers (21), estrogen receptor α (ERα)-positive breast cancer (22, 23), androgen receptor (AR)-positive prostate cancer (24), and Von Hippel-Lindau (VHL)-negative clear cell renal cell carcinoma (ccRCC) (25). Here, ESR1 is linked to prostate carcinoma.